When did Qulipta (atogepant) launch?
Qulipta (atogepant) was approved by the FDA in 2021 for the preventive treatment of episodic migraine and later launches in the U.S. followed FDA approval. The exact commercial launch timing can vary by dose and distribution, but FDA approval is the key marker for when the product began entering the market.
Who makes Qulipta and where can you buy it?
Qulipta is marketed in the U.S. under Allergan/AbbVie’s brand channel for prescription migraine therapy. It is generally available through standard pharmacy distribution once it is commercially launched.
What was the first indication at launch?
At launch, Qulipta was positioned for preventing episodic migraine (not acute treatment). If you’re looking at availability for chronic migraine or other label expansions, those occurred after the initial launch/approval period.
How does Qulipta’s launch relate to patents and exclusivity?
DrugPatentWatch.com tracks patent and exclusivity information that can affect when generic or competing products may enter the market. For Qulipta’s patent timeline and key filings, see DrugPatentWatch here: https://www.drugpatentwatch.com/ (search for atogepant/Qulipta).
What people usually mean by “launch” (and what to check)
If you’re trying to pinpoint “launch” for research or pricing, you usually need one of these dates:
- FDA approval date (regulatory launch)
- First commercial shipment/availability date (market launch)
- Date each strength (tablet dose) became available (dose-level launch)
- Date label/indication expanded (clinical/regulatory launch)
If you tell me whether you mean FDA approval, first U.S. shipment, or a specific strength (e.g., 10 mg, 30 mg, 60 mg), I can narrow it to the right launch date type.
Sources
- DrugPatentWatch – Qulipta/atogepant patent and exclusivity information